Oncobit raises 1.47 million francs

The Schlieren-based medtech start-up Oncobit, which specializes in cancer precision medicine, has raised 1.47 million Swiss francs from existing and new investors in a pre-Series A financing round, according to a press release. The funds will be used to generate additional clinical data in melanoma, expand Oncobit's monitoring platform to colorectal cancer and enter additional partnerships and markets, including the US, according to the company's press release.

"This financing round will allow us to invest in key product developments, accelerate our growth plans and continue to deliver value to our customers," said Claudia Scheckel, CEO and co-founder of Oncobit. The investors' commitment shows "the confidence they have in our ability to drive innovation in the field of cancer monitoring and to realize our vision of enabling personalized cancer care," Scheckel continued.

Oncobit offers various test methods, such as Oncobit DxM for the examination of tissue samples and Oncobit LBM for the examination of blood samples from melanoma patients. Melanoma, also known as black skin cancer, is the most malignant form of all skin cancers, according to the University Hospital Zurich.

Oncobit has received a CE mark for its product Oncobit PM BRAFV600, which is used to monitor response to treatment of minimal residual disease and disease recurrence in melanoma.

Oncobit was founded by doctors and scientists from the University Hospital Zurich and the Swiss Federal Institute of Technology Zurich(ETH) and is based in the Bio-Technopark Schlieren-Zurich. ce/gba